

Date: 14th February, 2026

To,
National Stock Exchange of India Limited
("NSE"), The Listing Department
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex
Bandra (East), Mumbai - 400 051.

NSE Symbol: **STALLION**
ISIN: **INE0RYC01010**

To,
BSE Limited ("BSE"),
Corporate Relationship Department,
2nd Floor, New Trading Ring,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

BSE Scrip Code: **544342**
ISIN: **INE0RYC01010**

Sub: **Monitoring Agency Report for the quarter ended on 31st December, 2025.**

Dear Sir/Madam,

Pursuant to Regulations 32(6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with Regulation 41(4) of Securities and Exchange Board of India (Issue of Capital Disclosure Requirements) Regulations 2018, as amended, please find enclosed Monitoring Agency Report issued by CARE Ratings Limited, Monitoring Agency, for the quarter ended on 31st December, 2025 with respect to the utilisation of proceeds of the Initial Public offer (IPO) of the company.

Yours Faithfully,

For Stallion India Fluorochemicals Limited
(Formerly known as Stallion India Fluorochemicals Private Limited)

Govind Rao
Company Secretary & Compliance Officer

No. CARE/HO/GEN/2025-26/1278

The Board of Directors

Stallion India Fluorochemicals Limited

2, A Wing, Knox Plaza, Off. Link Road,
Mindspace, Malad - (West), Mumbai – 400064

February 14, 2026

Dear Sir,

**Monitoring Agency Report for the quarter ended December 31, 2025 - in relation to the Initial Public Offer (IPO) of
Stallion India Fluorochemicals Limited (“the Company”)**

We write in our capacity of Monitoring Agency for the IPO for the amount aggregating to Rs.160.72 crore of the company and refer to our duties cast under Regulation 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended December 31, 2025 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated September 09, 2024.

Request you to kindly take the same on records.

Thanking you,

Yours faithfully



Ashish A Kambli

Associate Director

Ashish.K@careedge.in

Report of the Monitoring Agency

Name of the issuer: Stallion India Fluorochemicals Limited

For quarter ended: December 31, 2025

Name of the Monitoring Agency: CARE Ratings Limited

- 1 Deviation from the objects: Yes; In Q2FY26 Stallion India Fluorochemicals Limited has made excess utilization of ₹3.99 crore towards Issue expenses. Total Issues expenses specified in prospectus were ₹11.99 crore, however actual spending stood at ₹15.98 crore as on December 31, 2025 resulting in material deviation.
- 2 The details submitted in the management and Chartered Accountant certificate incorrectly captures issue expense under working capital. It reflects discrepancy in the data submission by the company. Refer to the detailed comments as mentioned below Table 4 (ii).

(b) Range of Deviation: 25-50%.

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have a credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature: 

Name of the Authorized Signatory: Ashish A Kambli

Designation of Authorized person/Signing Authority: Associate Director

1) Issuer Details:

Name of issuer : Stallion India Fluorochemicals Limited
Name of the promoter : Shazad Sheriar Rustomji
Industry/sector to which it belongs : Refrigerant and Industrial Gases

2) Issue Details

Issue Period : January 16, 2025 to January 20, 2025
Type of issue (public/rights) : IPO (Public)
Type of specified securities : Equity shares
IPO Grading, if any : NA
Issue size (in crore) : ₹ 160.72 crore

3) Details of the arrangement made to ensure the monitoring of the issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	No	Management Confirmation, CA certificate*, bank statements and Prospectus	<p>There is a delay in utilization of proceeds towards objects 2 and 3 related to funding capital expenditure as compared to prospectus. Further, in Q2FY26, the company made excess utilization of ₹3.99 crore towards Issue expenses. Total Issue expenses specified in prospectus were ₹11.99 crore, and actual spending stood at ₹15.98 crore as on December 31, 2025, resulting in material deviations from expenditures disclosed in the Offer Document.</p> <p>The utilization during the current quarter remains in line with the offer document with proceeds being routed through multiple current accounts which have numerous other transactions leading to commingling of funds.</p>	<p>The Industry standards changed from 200 bar to 300 bar for helium and entire plant and machinery had to undergo re-engineering to ensure we are having the latest plant upto latest industry standards. The Mambattu facility was expanded to full capacity which is twice what was as per capex. The reason is with the upcoming R-32 plant at Bhilwara, it was decided to enhance the plant to full capacity of 10 tanks and also helium and semiconductor gases and hydrocarbons rather than the 50% level as provided for in IPO objects (5 Tanks and only blending). The delay ensure s judicious use of funds which will enhance the company's ability and sale rather than make something which would need to be changes again at delays and additional costs.</p>

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	No	Management Confirmation, CA certificate* and Prospectus	<p>Shareholder approval is not available for the following deviations:</p> <ul style="list-style-type: none"> As per Prospectus, the funds allocated for issue expenses were ₹11.99 crore while the utilization towards issue expenses is ₹15.98 crore resulting in excess utilization ₹3.99 crore. <p>As per Prospectus, the funds allocated for working capital purpose were ₹95 crore. However, SFIL made total utilization of ₹98.71 crore till Q1FY26 (till Q4FY25: ₹94.14 crore; Q1FY26: ₹4.57 crore) which led to excess utilization of ₹3.71 crore.</p>	The surplus payments are on account of 188 times oversubscription and related extra unforeseen expenses of NSE/BSE/Banks/etc towards the 188 times oversubscription were paid for from company own funds.
Whether the means of finance for the disclosed objects of the issue have changed?	Yes	Management Confirmation, CA certificate* and Prospectus	The total excess utilization in certain objects is ₹7.70 crore. The said excess utilization will lead to deficit in available IPO proceeds for other specified objects.	There is no deficit in IPO proceeds towards any capex. The 3.71 cr allocated for GCP were used for working capital and have already been reported once and board approval was taken for the same. There is no impact or deficit in Capex
Is there any major deviation observed over the earlier monitoring agency reports?	Yes	Previous Monitoring Agency Report	The report issued in Q2FY26 was with deviation.	3.71 cr funds of GCP were moved to working capital and board approval was taken for the same.
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Management Confirmation, CA certificate*	Monitoring agency has primarily relied on CA certificate and Management Certificate	
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes	Management Confirmation, CA certificate*	Monitoring agency has primarily relied on CA certificate and Management Certificate	
Are there any favorable/unfavorable events affecting the viability of these object(s)?	Yes	Management Confirmation, CA certificate*	As stated above, the company has made excess utilization of IPO proceeds for certain objects as detailed in progress in the object table to the extent of ₹ 7.70 crore. The said excess utilization may impact the viability of the objects.	There is no impact to viability of project. Funds in GCP were moved to working capital and surplus funds including those amounts are available in FD and bank balances

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
			The delay in utilization of issue proceeds towards object 2 and 3 related to capital expenditure may affect the viability of the said objects.	
Is there any other relevant information that may materially affect the decision making of the investors?	No	-	-	

*Chartered Accountant certificate from Mittal & Associates dated February 10, 2026.

#Where material deviation may be defined to mean:

- Deviation in the objects or purposes for which the funds have been raised
- Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

4) Details of objects to be monitored:

(i) Cost of objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of -firm arrangements made
1	Working capital requirements	Management Certificate, CA certificate* and Prospectus	95.00	Not applicable	As per Prospectus, the funds allocated for working capital purposes were Rs.95 crore. However, SFIL made total utilization of Rs.98.71 crore till Q1FY26 (Q4FY25: Rs.94.14 crore; Q1FY26: Rs.4.57 crore) which led to excess utilization of Rs. 3.71 crore. Further in Q2FY26 it has excess utilization of Rs.3.99 crore towards Issue expenses. The total excess utilization in certain objects is Rs.7.70 crore. The said	GCP was not required and was moved to working capital where its more productively utilised and remains with the company instead of being spent in an expense.	Surplus funds are available with the company as the same can be seen in current balances. Company has enough funds not to have	There is no impact and no funds are short for any object. Rather then expense out GCP it was moved to working capital where it is used continually multiple times and remains
2	Funding capital expenditure requirements for our Semi-conductor & Specialty Gas debulking & blending facility ("Khalapur, Maharashtra")	Management Certificate, CA certificate* and Prospectus	29.16	Not applicable				
3	Funding capital expenditure requirements for our Refrigerant debulking & blending facility ("Mambattu, Andhra Pradesh")	Management Certificate, CA certificate* and Prospectus	21.17	Not applicable				
4	General Corporate Purpose	Management Certificate, CA certificate* and Prospectus	3.41	Not applicable				

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of -firm arrangements made
5	Share issue expenses	Management Certificate, CA certificate* and Prospectus	11.98	Not applicable	excess utilization could lead to deficit in available IPO proceeds for other specified objects.		deficit in any object	with the company
Total			160.72					

*Chartered Accountant Certificate from Mittal and Associates dated February 10, 2026

(ii) Progress in the objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in ₹ Crore	Amount utilised in ₹ Crore			Total unutilised amount in ₹ crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in ₹ Crore	During the quarter in ₹ Crore	At the end of the quarter in ₹ Crore			Reasons for idle funds	Proposed course of action
1	Working capital requirements	Management Certificate, CA certificate* and bank statements	95.00	98.71	0.00	98.71	(3.71)	Nil utilization during the quarter. Management and CA certificates have incorrectly classified the issue expenses under working capital purpose.	There is no idle funds its fully utilised	Based on opening & closing balances of last MA report the company (after discussion with MA) have to continue with closing balance as per last report. Its not wrong classification.
2	Funding capital expenditure requirements for our Semi-conductor	Management Certificate, CA certificate*,	29.16	9.81	5.73	15.53	13.63	During the quarter company has utilized the proceeds for making payments toward construction and related expenditure.	Company has detailed two ICICI accounts	Detailed expenses with bank statements with all payments

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in ₹ Crore	Amount utilised in ₹ Crore			Total unutilised amount in ₹ crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in ₹ Crore	During the quarter in ₹ Crore	At the end of the quarter in ₹ Crore			Reasons for idle funds	Proposed course of action
	& Specialty Gas debulking & blending facility ("Khalapur, Maharashtra")	Prospectus, Invoices and bank statements						There were multiple transactions routed through multiple current accounts which has numerous other transactions leading to commingling of funds. Monitoring Agency has relied on CA certificate, management certificate, invoices and other supporting documents.	which are used for forex and local payments and escrow account. Only these were considered	highlighted were provided and detailed discussion showing everything was provided and can have no ambiguity or confusion.
3	Funding capital expenditure requirements for our Refrigerant debulking & blending facility ("Mambattu, Andhra Pradesh")	Management Certificate, CA certificate*, Prospectus, Invoices# and bank statements	21.17	1.99	1.47	3.46	17.71	During the quarter company has utilized the proceeds for making payments toward construction and related expenditure. There were multiple transactions routed through multiple current accounts which has numerous other transactions leading to commingling of funds. Utilization is in line with the object, for which Monitoring Agency has relied on CA certificate, management certificate, invoices and other supporting documents.	Same as above	Same as above
4	General Corporate Purpose	Management Certificate, CA certificate*, Prospectus and bank statements	3.41	3.41	0.00	3.41	0.00	Utilization completed under this object.		
5	Share issue expensed	Management Certificate, CA	11.98	15.99	0.00	15.99	(3.99)	Nil utilization during the quarter.		

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in ₹ Crore	Amount utilised in ₹ Crore			Total unutilised amount in ₹ crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in ₹ Crore	During the quarter in ₹ Crore	At the end of the quarter in ₹ Crore			Reasons for idle funds	Proposed course of action
		certificate*, Prospectus and bank statements								
Total			160.72	129.91	7.20	137.10	23.62			

*Chartered Accountant Certificate from Mittal and Associates dated February 10, 2026.

#Verified through invoices and other supporting documents

(iii) Deployment of unutilized proceeds:

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter
1	ICICI Bank FD (9927)	0.10	March 06, 2026	-	6.70	0.10
2	ICICI Bank FD (4943)	0.01	July 30, 2026	-	6.25	0.01
3	ICICI Bank FD (9876)	0.10	February 25, 2026	-	6.70	0.10
4	ICICI Bank FD (9941)	0.10	March 11, 2026	-	6.70	0.10
5	ICICI Bank FD (9944)	0.10	March 12, 2026	-	6.70	0.10
6	ICICI Bank FD (0152)	0.10	May 06, 2026	-	6.70	0.10
7	ICICI Bank FD (0548)	15.00	September 18, 2026	-	6.70	15.00
8	Axis Escrow account (Account Number: 924020054061481)	0.35	-	-	-	0.35
9	ICICI Bank Current account (Account No: 122105000039)	*7.53	-	-	-	7.53
10	ICICI Bank Current account (Account No: 122105000384)	0.20	-	-	-	0.20
Total		23.62				

Verified from FD receipt of ICICI Bank and Bank statements of ICICI bank and Axis Bank.

Chartered Accountant certificate from Mittal and Associates dated February 10, 2026.

Remarks: *The unutilized proceeds in current account have been derived as a balancing figure when compared to unutilized proceeds. The company has utilized the proceeds though current account which has numerous other debits and credits resulting in comingling of funds. The balance of the current account (122105000039) is ₹ 31.14 crore as on December 31, 2025 as against estimated balance of ₹7.53 crore. Monitoring Agency notes that un-utilized balance as per management certificate and CA certificate includes other balances which are not pertaining to IPO proceeds.

Axis bank and ICICI bank are the scheduled banks under the second schedule of RBI Act, 1934 as per the requirements for deposit of interim use of proceeds in the prospectus

(iv) Delay in implementation of the object(s):

Objects	Completion Date		Delay (no. of days/months)	Comments of the Board of Directors	
	As per the offer document*	Actual		Reason of delay	Proposed course of action
Working capital requirements	March 31, 2026	June 30,2025	No delays		
Funding capital expenditure requirements for our Semi-conductor & Specialty Gas debulking & blending facility ("Khalapur, Maharashtra").	October 30, 2025	Ongoing	Delay (Exact number of days not ascertainable)	Re-engineering requirements to meet enhances Industry standards of 300 bar (up from earlier 200 bar)	Completion expected in march 2026 and startup in in April 2026
Funding capital expenditure requirements for our Refrigerant debulking & blending facility ("Mambattu, Andhra Pradesh")	October 30, 2025	Ongoing	Delay (Exact number of days not ascertainable)	The company enhanced the project from a 2 working shed and 5 tank project into a 10 tank and 4 working shed project and also included Helium and semiconductor gases and hydrocrbons at this facility which doubled the scope and required complete re-engineering	Project is on track and will see completion and startup by May 2026. Monsoons and extreme flooding at location had also impacted the project and entire factory land height was raised 4 feet above existing ground to ensure there are no issues onwards once plant starts operations. Board had been updated and appreciated the forward planning and enhancement of project done which will greatly enhance company operations onwards after startup.
General Corporate Purpose	March 31, 2026	June 30,2025	No delays		
Share issue expensed	March 31, 2025	March 31, 2025	No delays		

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head[^]	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
<i>No utilization during Q3FY26</i>					

[^] Section from the offer document related to GCP: "We will have flexibility in utilizing the balance Net Proceeds, if any, for general corporate purposes, aggregating to Rs 340.88 Lakhs, subject to such utilization not exceeding 25% of the Gross Proceeds from the Fresh Issue in accordance with Regulation 7(2) of the SEBI ICDR Regulations, including but not restricted towards strategic initiatives, improvement in supply chain, branding, marketing, rental and administrative expenses, meeting exigencies, and expenses incurred in the ordinary course of business. The quantum of utilization of funds toward the aforementioned purposes will be determined by our Board based on the amount actually available under the head "General Corporate Purposes" and the corporate requirements of our Company, from time to time."

Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as “**Monitoring Agency/MA**”). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditor (or from peer reviewed CA firms), appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from statutory auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.